GW Pharma: World Leader in Cannabis Science
-
Upload
yi-liu -
Category
Economy & Finance
-
view
703 -
download
0
Transcript of GW Pharma: World Leader in Cannabis Science
![Page 1: GW Pharma: World Leader in Cannabis Science](https://reader036.fdocuments.us/reader036/viewer/2022081513/58ed42b41a28ab7a5c8b45c1/html5/thumbnails/1.jpg)
Project 10: GWPHLiu, Yi and Zhou, Bo08-30-2015PSIC © http://pstrand.com
![Page 2: GW Pharma: World Leader in Cannabis Science](https://reader036.fdocuments.us/reader036/viewer/2022081513/58ed42b41a28ab7a5c8b45c1/html5/thumbnails/2.jpg)
Legalization of Marijuana (Cannabis)Marijuana, once a useful herb medicine in history, has been classified as a strictly controlled psychoactive substance in the last century. Recently, the need for medical use and the desire for recreational use have driven many legislations to loosen the control.
Nature Outlook Special Issue (09.2015):
www.nature.com/nature/outlook/cannabis
**Marijuana Research Supports Its Safety and Benefits (2015)
神农
![Page 3: GW Pharma: World Leader in Cannabis Science](https://reader036.fdocuments.us/reader036/viewer/2022081513/58ed42b41a28ab7a5c8b45c1/html5/thumbnails/3.jpg)
Medical Potentialhttp://upliftingwellness.org/medical-cannabis/
![Page 4: GW Pharma: World Leader in Cannabis Science](https://reader036.fdocuments.us/reader036/viewer/2022081513/58ed42b41a28ab7a5c8b45c1/html5/thumbnails/4.jpg)
Challenge and mismatch in use vs knowledge
1. Lack of research: Research has been undermined by a lingering assumption that all cannabinoids share the properties of THC (responsible for psychoactivity) — and regulators apply the same restrictions to all of them
2. How will rising use resulted from looser control affect public health?
http://www.nature.com/nature/journal/v525/n7570_supp/full/525S4a.html
![Page 5: GW Pharma: World Leader in Cannabis Science](https://reader036.fdocuments.us/reader036/viewer/2022081513/58ed42b41a28ab7a5c8b45c1/html5/thumbnails/5.jpg)
Cannabis compounds: gold mine?
http://www.nature.com/nature/journal/v525/n7570_supp/full/525S2a.html
![Page 6: GW Pharma: World Leader in Cannabis Science](https://reader036.fdocuments.us/reader036/viewer/2022081513/58ed42b41a28ab7a5c8b45c1/html5/thumbnails/6.jpg)
GWPH is world leader in Cannabinoid scienceCompany Web Lead Product Financial
InSys www.insysrx.com/ Cannabidiol Oral Solution (CBD)
INSY (2.7B)
Cannabis Science http://www.cannabisscience.com/ Phase I OTC:CBIS ($0.01/shr, 18M)
Inmed Pharma http://www.inmedpharma.com Pre-clinical OTC:IMLFF (MCap: 8M)
Phytecs http://www.phytecs.com/ Not focused. Also covers food, cosmetics Private
![Page 7: GW Pharma: World Leader in Cannabis Science](https://reader036.fdocuments.us/reader036/viewer/2022081513/58ed42b41a28ab7a5c8b45c1/html5/thumbnails/7.jpg)
GW Pharma: Leader in Cannabis science
![Page 8: GW Pharma: World Leader in Cannabis Science](https://reader036.fdocuments.us/reader036/viewer/2022081513/58ed42b41a28ab7a5c8b45c1/html5/thumbnails/8.jpg)
Controlled cultivation● Concentrations of active substances vary a lot in marijuana products sold in stores. ● High levels of chemical consistency are important in applications made to medical regulatory
authorities. ● At GW Pharmaceuticals' growing facility, cannabis clones are grown to ensure chemical
consistency and to meet commercial supply capacity.
![Page 9: GW Pharma: World Leader in Cannabis Science](https://reader036.fdocuments.us/reader036/viewer/2022081513/58ed42b41a28ab7a5c8b45c1/html5/thumbnails/9.jpg)
Pipeline1. One “partnered” product
approved in EU. 2. One product in phase III
with two indications: two types of childhood epilepsy.
![Page 10: GW Pharma: World Leader in Cannabis Science](https://reader036.fdocuments.us/reader036/viewer/2022081513/58ed42b41a28ab7a5c8b45c1/html5/thumbnails/10.jpg)
EpidiolexCannabidiol
a major phytocannabinoid
accounting for up to 40% of the plant's extract.[5]
have a wider scope of medical applications than tetrahydrocannabinol (THC).
An orally-administered liquid containing CBD has received orphan drug status in the US, for childhood epilepsy.
![Page 11: GW Pharma: World Leader in Cannabis Science](https://reader036.fdocuments.us/reader036/viewer/2022081513/58ed42b41a28ab7a5c8b45c1/html5/thumbnails/11.jpg)
Childhood epilepsy: unmet medical needs
![Page 12: GW Pharma: World Leader in Cannabis Science](https://reader036.fdocuments.us/reader036/viewer/2022081513/58ed42b41a28ab7a5c8b45c1/html5/thumbnails/12.jpg)
Dravet Syndrome 1. Syndromes are highly
fragmented.
2. Dravet syndrome is a severe infantile-onset, genetic, drug-resistant epilepsy syndrome with a distinctive but complex electroclinical presentation.
3. 5,440 patients in US and 6,710 patients in EU under 20 [vii], [viii].
4. no FDA approved treatments[xii]. SOC usually involves a combination of anticonvulsants: clobazam, clonazepam, levetiracetam, topiramate and valproic acid .
![Page 13: GW Pharma: World Leader in Cannabis Science](https://reader036.fdocuments.us/reader036/viewer/2022081513/58ed42b41a28ab7a5c8b45c1/html5/thumbnails/13.jpg)
Lennox-Gastaut syndromeLGS, is a rare disorder characterized by multiple types of seizures with slow spike wave
complexes on EEG, such seizures usually beginning before 4 years of age.
14,000 – 18,500 patients in US [vi] and 23,000 – 31,000 patients in EU under 18.
Drug resistance is one of the main features of LGS[vii]. Often requires broad spectrum anti-epileptic drugs and/or polypharmacy[viii]. It will also depend on the seizure type as some treatments that are effective for one type of seizure may worsen another. The treatments already approved by the FDA for LGS and used as adjunctive therapy with existing medications are: Onfi (clobazam); Banzel (rufinamide); - Topamax (topirimate)).
http://www.gwpharm.com/Lennox-Gastaut.aspx
![Page 14: GW Pharma: World Leader in Cannabis Science](https://reader036.fdocuments.us/reader036/viewer/2022081513/58ed42b41a28ab7a5c8b45c1/html5/thumbnails/14.jpg)
Trial efficacy resultsOnly median, no distribution (stdev) results provided.
9% total pts, 16% Dravet patients were seizure free after treatment.
![Page 15: GW Pharma: World Leader in Cannabis Science](https://reader036.fdocuments.us/reader036/viewer/2022081513/58ed42b41a28ab7a5c8b45c1/html5/thumbnails/15.jpg)
Epidiolex Trial Design: 2nd Darvet and LGS
Add placebo control and randomized. previous trials were either controlled or randomized
![Page 16: GW Pharma: World Leader in Cannabis Science](https://reader036.fdocuments.us/reader036/viewer/2022081513/58ed42b41a28ab7a5c8b45c1/html5/thumbnails/16.jpg)
Safety: lots of SAEs
SAEs that were deemed possibly treatment related
occurred in 10% patients
![Page 17: GW Pharma: World Leader in Cannabis Science](https://reader036.fdocuments.us/reader036/viewer/2022081513/58ed42b41a28ab7a5c8b45c1/html5/thumbnails/17.jpg)
Chance of approval1. Neurology low first round rate 37%2. lots of SAEs3. Controversial Marijuana4. First time NDA, small company
}=> First round CRL
Effective with some patients. FDA will eventually approve it.
![Page 18: GW Pharma: World Leader in Cannabis Science](https://reader036.fdocuments.us/reader036/viewer/2022081513/58ed42b41a28ab7a5c8b45c1/html5/thumbnails/18.jpg)
GW Pharma: peak sales of pipeline productsEdison's healthcare team forecasts peak sales for [link]:
Epidiolex in Dravet syndrome (DS) of $288m, THC/CBD (GBM) of $246mGWP42004 (type 2 diabetes) of $1,025m. Sativex peak sales potential of $814m – MS Spasticity at $278m (US $176m,
ex-US $102m) and cancer pain at $536m (US $350m, ex-US $186m).
![Page 19: GW Pharma: World Leader in Cannabis Science](https://reader036.fdocuments.us/reader036/viewer/2022081513/58ed42b41a28ab7a5c8b45c1/html5/thumbnails/19.jpg)
Financial
- Valuation:- 12.2013 $48~59/share [link]- 04.2015 $~80/share [link]
- Technical analysis: - downtrend along with bear market- a few price gaps to be filled (see pic)
- 财报 : little debt (funded by equity); expense up big recently due to phase III trial- public offering
- $8.9 5.01.2013 (cheap IPO; was an ignored gem)- $86.83 6.18.2014 (We should buy at most half price of these guys)- $112 4.28.2015
![Page 20: GW Pharma: World Leader in Cannabis Science](https://reader036.fdocuments.us/reader036/viewer/2022081513/58ed42b41a28ab7a5c8b45c1/html5/thumbnails/20.jpg)
PSIC RecommendationAs of 9.27.2015: 1. GWPH, leader in cannabis science, is a good company.
2. Downtrend of GWPH and biotech sector in general is apparent. GWPH is overvalued at this price ($99).
3. Bear market will probably bring down the price further. It will be more attractive below $40, or even $20.
4. Let’s be patient and wait for the bear to do its job.